

Abstract of the Disclosure

The invention relates to a combination therapy for treating patients suffering from diseases characterized by cell proliferation and infiltration of inflammatory cells, coronary diseases, hypertension, renal diseases, diabetes, or ocular diseases and conditions. The patient is treated with a combination of:

- (a) a VEGF inhibitor compound; and
- (b) one or more second therapeutic agents selected from the group consisting of:
 - i. angiostatic steroids;
 - ii. photosensitizers;
 - iii. implants containing corticosteroids;
 - iv. AT1 receptor antagonists;
 - v. ACE inhibitors;
 - vi. cyclooxygenase inhibitors;
 - vii. IGF-IR inhibitors;
 - viii. mTOR kinase inhibitors;
 - ix. somatostatin receptor antagonists;
 - x. PI3K inhibitors;
 - xi. Raf kinase inhibitors;
 - xii. PKC inhibitors;
 - xiii. integrin antagonists;
 - xiv. endogenous anti-angiogenic molecules; and
 - xv. PEDF and analogs.